<scp>EndoBarrier</scp> treatment for longstanding type 2 diabetes and obesity: outcomes one year after <scp>EndoBarrier</scp> in 90 consecutively treated patients

Ryder, Robert EJ; Yadagiri, Mahi; Burbridge, Wyn; Irwin, Susan; Gandhi, Hardeep; Bashir, Tahira; Allden, Rachael A; Wyres, Melanie C.; Cull, Melissa L.; Bleasdale, John; Fogden, Edward; Anderson, Mark R.; Gupta, Piya Sen

doi:10.1002/pdi.2393

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings enhance our previous reports of considerable improvement in weight, glycaemic control, cardiovascular risk, renal function and a marker of liver fat as well as a reduction in the need for insulin that we found for EndoBarrier treatment in the first NHS service. 6,11,[17][18][19] This is the first study to follow patients for three years after the removal of EndoBarrier.…”

Section: Discussionmentioning

confidence: 99%

“…This led to a total of 90 EndoBarrier-treated people with diabetes and at one year after EndoBarrier 80% maintained significant improvement. 18 Confidence in the longevity of EndoBarrier treatment would be increased further by improvement maintained beyond one year. We therefore aimed to follow our people with diabetes for a further two years to evaluate further the extent to which the benefits of EndoBarrier treatment were, or were not, sustained.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the ﬁrst National Health Service (NHS) EndoBarrier service

et al. 2022

View full text Add to dashboard Cite

Background and aims: EndoBarrier is a 60cm duodenal-jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the bypass part of roux-en-Y bariatric surgery. There is uncertainty concerning the extent to which improvements associated with EndoBarrier treatment are sus-tained once the liner has been removed. We aimed therefore to establish an EndoBarrier service for refractory diabesity and to continue to monitor the people with diabetes after EndoBarrier removal. Methods: Between October 2014 and November 2017, we implanted 62 EndoBarriers in our NHS service. All had been removed by November 2018. Outcomes were monitored in a registry. Results: As of November 2021, all patients reached three years after EndoBarrier removal and of these 43/62 (69%) (mean±SD age 51.6 ± 7.6 years, 55.8% male, 55.8% white ethnicity, median [IQR] diabetes duration 14.6 [8 – 21] years, 62.8% insulin-treated, mean±SD BMI 41.7±7.3 kg/m2) attended follow-up. In those who attended, during EndoBarrier implantation mean±SD HbA1c fell by 20.6±19.6 mmol/mol from 76.3±19.2 to 55.7±11.1 mmol/mol (p<0.001) (by 1.9±1.8% from 9.1±1.8% to 7.2±1.0% [p<0.001]), weight fell by 17.4±9.1 kg from 123.3±30.0 kg to 105.9±30.8 kg (p<0.001), BMI fell from 41.7±7.3 to 35.6±7.7 kg/m2 (p<0.001), systolic blood pressure from 138.7±14.4 to 125.4±14.7 mmHg (p<0.001), cholesterol from 4.6±1.0 to 3.7±0.7mmol/L (p<0.001), and serum alanine aminotransferase from 30.8±17.2 to 19.3±11.2 U/L (p<0.001). In those taking insulin median (IQR) total daily insulin dose reduced from 114 (54–180) to 20 (0–65) units (n=27, p<0.001); 10/27 (37%) insulin-treated people were able to discontinue insulin. Three years after EndoBarrier removal 33/43 (77%) maintained most of the improvement achieved with EndoBarrier whilst 10/43(23%) reverted to baseline. Of those deteriorating 9/10(90%) had depression and/or bereavement and/or major health problems/disability. 10/62(16%) required early Endo-Barrier removal for adverse events or symptoms; all 10 fully recovered after removal and most derived signiﬁcant beneﬁt. Conclusions: Our data demonstrate that EndoBarrier is highly effective in people with refractory diabesity, with mainte-nance of signiﬁcant improvement three years after removal in 77% of cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the ﬁrst National Health Service (NHS) EndoBarrier service

et al. 2022

View full text Add to dashboard Cite

show abstract

Updates in Endoscopic Bariatric and Metabolic Therapies

Qureshi

Saeed

Jovani

2023

JCM

View full text Add to dashboard Cite

The rising prevalence of obesity, and related morbidity and mortality, has necessitated the development of therapeutic weight loss strategies. Lifestyle modifications alone have only yielded modest benefit, and while bariatric surgery has shown significant short- and long-term results, only a minority of eligible patients end up receiving this treatment. Endoscopic bariatric and metabolic therapies (EBMTs) are a rapidly evolving field, which provides a less invasive middle ground treatment option for weight loss. Here we discuss the efficacy, as well as short- and long-term outcomes with restrictive, malabsorptive/metabolic and aspiration endoscopic techniques, and their effects on metabolic parameters.

show abstract

EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients

Cited by 2 publications

References 12 publications

Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the ﬁrst National Health Service (NHS) EndoBarrier service

Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the ﬁrst National Health Service (NHS) EndoBarrier service

Updates in Endoscopic Bariatric and Metabolic Therapies

Contact Info

Product

Resources

About